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Background and aims
Diabetes mellitus is characterized by hyperglycemia due to impaired insulin secretion, insulin action or both, which results in abnormalities in the metabolism of carbohydrates, fats and proteins [1] . Diabetes mellitus (DM) is a global health problem. The prevalence of diabetic patients continues to increase yearly and it is estimated more than 80% of people with diabetes are in developing countries [2] . Diabetes mellitus is a metabolic disease that often leads to macrovascular and microvascular complications [1] . Hyperglycemia in diabetes leads to excessive production of free radicals [3] . Excessive production of free radicals is a major factor causing complications in DM [4] . According to Basu et al. [5] , one of the causes for hyperglycemia is increased gluconeogenesis. High blood glucose levels in diabetic patients might be caused by overexpression of the enzyme phosphoenolpyruvate carboxykinase (PEPCK), a key enzyme in gluconeogenesis, thus reducing PEPCK gene expression may improve the hyperglycemia [6] . Increased expression of PEPCK in DM patients may be due to an elevated expression of the retinol binding protein-4 (RBP-4) in adipocytes [7] . The elevated expression and RBP-4 levels in adipose tissue and liver is known to trigger insulin resistance in humans and animal experimental models [8] [9] [10] .
Indonesia has about 30,000 species of plants and some of these plants show anti-diabetic activity. Active medicinal plants for treating diabetes include pariah (Momordica charantia L.), green tea (Camellia sinensis), ginseng (American Ginseng-Panax quinquefolium L.) [11] , pomegranate (Punica granatum L), jamun (Eugenia jambolana L) [12] and mahogany (Swietenia macrophylla King).
Mahogany (Swietenia macrophylla King) is a species of the Meliaceae family. Mahogany seeds have been widely used by the community as a traditional medicine for people with DM. Mursiti [13] found that the oil-free extract of mahogany seeds contains alkaloid, flavonoid and saponin compounds. Flavonoids consist of a polyphenolic compound. Some research suggests that flavonoid, or phenol has an antihyperglycemic activity. According to a study by Vessal et al. [14] , quercetin shows antidiabetic activity by regenerating pancreatic beta cells and increasing insulin secretion streptozotocininduced diabetic rats. Logendra et al. [15] showed that PEPCK expression in these rat models was reduced after administration of polyphenols contained in the Atermisia dracunculus ethanol extract, namely phenoxy chromon and dihydrochalcone.
This research aimed to assess the potential of antidiabetic flavonoid compounds (7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl) -chroman-4-one) in mahogany seeds.
Materials and methods
Animals
Thirty rats (30) male Wistar rats, (average weight of 200 g, 8 weeks old), were obtained from the Jakarta Food and Drug Control Agency (Balai POM Jakarta). They were housed in cages in an animal room (22-25°C room temperature on a 12-hour daylight cycle); food and water were given ad libitum during the experimental period using standard diet (AIN 93M). The standard diet in the experiment consisted of casein 24%, DL-Methionin 0.30%, cornstarch 61%, vitamin mix 1%, mineral mix 3.5%, choline chloride 0.2%, alpha cell 5% and corn oil 5%. This study was approved by the Ethics Committee of Faculty of Medicine, University Gadjah Mada. 
Induction of type 2 Diabetes Mellitus
Preparation of Flavonoid
Seven-hydroxy-2-(4-hydroxy-3-metoxyphenyl)-chroman-4-one was isolated from Swietenia macrophylla King seeds as previously reported by Mursiti S [13] .
Experimental studies
After the induction of diabetes, the animals were separated in several groups. Group 1 (normal animals without diabetes induction), group 2 (diabetic animals without treatment), group 3 followed a treatment with metformin while group 4, 5, and 6 treatment with 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one in concentrations of 10 mg, 30 mg, and 90 mg/200 g BW respectively. All treatments were administred by gavage for a period of four weeks. At the beginning (before treatment) and at the end of the experimental period (four weeks), blood samples were collected from retro orbitalis plexus after the animals had fasted for 10 hours. Blood samples were collected to analyze plasma glucose, insulin serum and homeostatic model assessment of insulin resistance (HOMA-IR). At the end of the experimental period (post test), animal were anaesthetized and euthanized and the liver was examined for RBP-4 and PEPCK gene expression.
Blood biochemical examination
Plasma glucose level was assayed by enzymatic glucose-peroxidase (GOD-POD) method (Diasys 
Isolation of RNA
Total RNA was obtained using TriZol ® reagent. The procedure followed the protocol provided by the TriZol ® reagent.
[17]
PEPCK and RBP-4 expression analysis by real-time PCR
The cDNA was synthesized using an iScript mix Biorad ® kit according to the protocol of the producer. SsoFast™Evagreen 
Statistical analysis
The results were expressed as the mean ± SE. The effects of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenlyl)-chroman-4-one on blood glucose, serum insulin, HOMA-IR, PEPCK and RBP-4 gene expression were analyzed by oneway ANOVA. Data were considered statistically significant if p values were lower than 0.05.
Results
The effect of flavonoid 7-hydroxy-2-(4-hydroxy-3-mehtoxy-phenyl)-chroman-4-one on blood glucose levels the diabetic rats is shown in Table 1 . .001 <0.001 P value in the last row indicate difference between groups. P value in the right indicate difference between pre and post. * difference significant between normal with diabetic rats, diabetic with metformin, diabetic rats with 7-hydroxy with three diference dosage. ** difference significant between diabetic rats with normal rats, diabetic with metformin, diabetic rats with 7-hydroxy with three diference dosage .001 P value in the last row indicate difference between groups. P value in the right indicate difference between pre and post. * difference significant between normal with diabetic rats, diabetic with metformin, diabetic rats with 7-hydroxy with three diference dosage. ** difference significant between diabetic rats with normal rats, diabetic with metformin, diabetic rats with 7-hydroxy with three diference dosage
The blood glucose levels in groups 3, 4, 5 and 6 decreased with 53.8%, 37.5%, 44.5% and 52.7% respectively (p<0.05) after four weeks treatment with metformin, respectively 7-hydroxy-2-(4-hydroxy-3-methoxy-phenly)-chroman-4-one. The 90 mg/200 g BW dose of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one had the same activity as metformin in reducing blood glucose levels.
The insulin levels of rats treated with flavonoid 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one dose of 10 mg, 30 mg, and 90 mg/200 g BW for 4 weeks s increased by 26.7%, 17.7%, and 4.8%, respectively (Table 2 ).
In Table 3 we showed that the administration of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one decreased significantly (p<0.05) the HOMA-IR value.
There is a significant differrence (p<0.05) between the 6 groups in the hepatic PEPCK gene expression after treatment with the 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one as shown in Figure 1 . In this study, the relative expression of PEPCK gene in DM rats that were given a 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one dose of 90 mg / 200g BW was smaller than in DM mice that were given a dose of 10mg, 30mg / 200g BW or DM mice without treatment (Figure 1) . <0,001 P value in the last row indicate difference between groups. P value in the right indicate difference between pre and post. * difference significant between normal with diabetic rats, diabetic with metformin, diabetic rats with 7-hydroxy with three diference dosage. ** difference significant between diabetic rats with normal rats, diabetic with metformin, diabetic rats with 7-hydroxy with three diference dosage DNA melting curve (Figure 2) after administration of the compound 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one show that at a low temperature, all amplicons (amplified cDNA products) were present as a double-stranded DNA (DsDNA) and began to bind the EvaGreen ® fluorescent dye generating a strong signal. Increasing the temperature causes the cDNA products to undergo denaturation and the fluorescence signal decreases until it reaches the melting temperature of the target cDNA product. The melting temperature of the PEPCK gene began to be detected at 84 o C and melting temperatures beta-actin began to be detected at 80°C. The yield curve cDNA amplification products with RT-PCR is represented in Figure 4 , having on x-axis the number of PCR cycles and on the y-axis the amount of amplification of the signal that is proportional to the number of fluorescence cDNA products that are amplified. The meeting point of the fluorescence signal over the line threshold (green line) is expressed as the value of C T. C T value of PEPCK gene began to be detected at 19.5 while the value of C T cycle control genes (beta-actin) began to be detected at 22 cycles.
There was no significant difference (p>0.05) in hepatic RBP-4 gene expression after four weeks treatment with 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one as shown in Figure 5 . In this study, the relative expression of RBP-4 gene that normal mice, untreated DM and metformin treated DM was similar. However, DM rats treated with flavonoid 7-hydroxy-2- As shown in Figure 6 , the DNA melting curve shows that at low temperatures, all amplicons (amplified cDNA product) are a double-stranded DNA (DsDNA) and began to bind the EvaGreen ® fluorescent dye generating a strong signal. Increasing the temperature causes the cDNA products to undergo denaturation and fluorescence signal decreases until it reaches the melting temperature of the target cDNA product. The melting temperature of the RBP-4 begins to be detected at 80°C and the melting temperatures of beta-actin begin to be detected at 86 o C. Figure 7 shows the melting curve peaks of RBP-4 gene that is the maximum point of detecting fluorescence signal. Different amplicons generate DNA melting curve peaks at different temperatures. The melting curve peak for RBP-4 gene DNA products is detected at 84,5 o C (blue) while the peak melting curve betaactin is detected at 83 o C (red).
Legend: blue -RBP-4 gene, red -beta actin control gene Legend: green -threshold, blue -RBP-4 gene, red -beta actin control gene, and light blue -no template control (NTC).
Figure 8. Amplification curve RBP-4 gene
The yield curve cDNA amplification products with RT-PCR is represented in
The yield curve cDNA amplification products with RT-PCR is represented in Figure 8 having on the x-axis the number of PCR cycles and on the y-axis the amount of amplification of the signal that is proportional to the number of fluorescence cDNA products that are amplified. The meeting point of the fluorescence signal over the line threshold (green line) is expressed as the value of C T. C T value of RBP-4 gene began to be detected at 18 while the value of C T cycle for control genes (beta-actin) began to be detected at 21 cycles.
Discussion
In the present study, we examined the effect of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl) chroman-4-one on levels of glucose, insulin, HOMA-IR, and PEPCK and RBP-4 expression in type 2 diabetic rats. Blood glucose levels were significantly reduced. The groups treated with 7-hydroxy-2-(4 hydroxy-3-methoxy-phenyl)-chroman-4-one at doses of 10 mg, 30 mg, and 90 mg/ 200 g BW had the same effect on blood glucose levels as that of metformin. These observations are in agreement with those of Falah et al. (2010) [17] who investigated the effect of Swietenia macrophylla seed extraction in alloxan induced diabetic rats, and Debasis et al. (2011) [18] who reported the effect of aqueous methanolic Swietenia macrophylla extract in streptozotocin induced diabetic rats. Based on these results, 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one may stimulate insulin release and therefore produce the observed restoration of metabolic activities.
In our study, in the group treated with the 10 mg/ 200 g BW of the extract there was an increase of insulin levels and a significant reduction in HOMA-IR values (Tables 2 and 3) . Increased insulin levels have reached the level found in normal rats, although HOMA-IR value was still not as in the normal group. This indicates that administration of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman 4-one dose of 10 mg/200 g BW was able to increase insulin production in pancreatic beta cells but was not able to completely overcome insulin resistance. The groups treated with the higher doses of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chroman-4-one had actually increased insulin levels but lower than the 10 mg/200 g BW group. Higher doses were more beneficial to overcome insulin resistance even though the decreased HOMA-IR value in the diabetes group that was treated with 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one dose of 90 mg/200 g BW has not reached the HOMA-IR value of the normal group (6.15 versus 13.87).
The decrease in HOMA-IR was in line with a decrease in PEPCK expression. Hyperglycemia in diabetic patients might be caused by over-expression of the enzyme PEPCK through oxidative stress [6] . The group that was treated with 90 mg/200 g BW had the highest ability to suppress PEPCK expression in liver.
Increased expression of PEPCK in DM patients may be due to an elevated expression of the retinol binding protein-4 (RBP-4) in the adipose tissue [7] . The elevated expression of RBP-4 gene in adipose tissue and the liver is known to trigger insulin resistance in humans and animal experimental models [8] [9] [10] . Thus, the induction of diabetes enhances RBP-4 expression in liver tissue. RBP-4 increases the expression of PEPCK, which leads to increased hepatic glucose output that serves to raise blood glucose [8] . Treatment with 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one at doses of 10 mg, 30 mg, and 90 mg/ 200 g BW reduced RBP4 expression most effectively compared to metformin. Flavonoid as an antioxidant is capable to inhibit oxidative stress, therefore reducing RBP-4 levels. By reducing RBP-4 level, insulin sensitivity will improve, so PEPCK level will also decrease. Flavonoid is able to induce reduction of aldose reductase, pancreatic cell regeneration and increase insulin release and Ca 2+ uptake, making it beneficial for treatment of diabetes mellitus [19] .
Conclusion
In conclusion, the results of this study show that the administration of 10 mg, 30 mg, and 90 mg/200 g BW of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one significantly (p<0.05) reduced blood glucose levels. In addition, the dose of 10 mg/200 g BW increased insulin levels and down regulated the gene expression of PEPCK in the liver.
